Ascendis Pharma Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw rapid revenue growth and profitability, driven by the FDA approval of YUVIWEL and strong uptake of YORVIPATH and SKYTROFA. Total revenue reached EUR 247 million, with robust patient and prescriber growth, and a strengthened balance sheet through asset sales and debt redemption.
-
YUVIWEL is set for a U.S. launch in early Q2 following FDA approval, targeting both untreated and switch patients with a differentiated weekly dosing profile and strong safety data. Pricing will reflect its clinical benefits, and international expansion is planned.
-
YUVIWEL received FDA approval as the first once-weekly therapy for children with achondroplasia, showing significant efficacy and safety in clinical trials. Commercial launch is planned for early Q2 2026, with label expansion and international rollout to follow.
-
Full-year 2025 revenue reached $1.86 billion, with Elevidys and PMOs as key drivers and strong profitability maintained. Major 2026 initiatives focus on expanding Elevidys' reach, advancing a robust siRNA pipeline, and leveraging newborn screening for earlier Duchenne intervention.
-
The phase 2 Coach trial in children with Achondroplasia showed that combining TransCon CNP and Growth Hormone led to unprecedented annualized growth velocities, significant improvements in body proportionality and arm span, and a strong safety profile. These results set a new benchmark for efficacy and support advancing to phase 3.
Fiscal Year 2025
-
Strong revenue growth in 2025 driven by YORVIPATH and SKYTROFA, with expanding global launches and robust pipeline progress. Guidance targets EUR 500 million operating cash flow in 2026 and EUR 5 billion annual revenue by 2030, supported by a solid cash position and ongoing label expansions.
-
Q3 2025 saw strong global growth for Yorvipath and SKYTROFA, with Yorvipath revenue at EUR 143 million and over 4,250 U.S. patients. Operating profit turned positive, and cash reserves increased to EUR 539 million. Continued revenue growth is expected, driven by new launches and label expansions.
-
TransCon technology drives a robust pipeline with three key products targeting rare diseases and growth disorders. YORVIPATH’s launch is progressing with strong U.S. uptake and global expansion, while TransCon CNP offers unique clinical benefits. Financial independence and operational efficiency support continued growth.
-
Q2 2025 saw strong revenue growth, led by YORVIPATH's global launch and SKYTROFA's label expansion. The company expects to achieve cash flow positivity this year, with continued momentum from new approvals and robust uptake across key products.
-
The COACH phase 2 interim results show that combining TransCon CNP and Growth Hormone in children with achondroplasia led to unprecedented growth acceleration, with annualized growth velocities exceeding the 97th percentile for average-stature children and significant improvements in body proportionality, all with a favorable safety profile. Phase 3 trials are planned to confirm these findings.
-
Yorvipath's US launch drove a major revenue increase and high patient uptake, while Skytrofa maintained strong market share and stable pricing. Substantial revenue growth is expected in 2025, with continued expansion and positive clinical progress across the portfolio.
-
Yorvipath's US launch targets a large, previously underserved patient pool, with rapid prescriber expansion and strong revenue growth. European rollout is progressing, with broader reimbursement expected by 2026. The pipeline includes a promising combo trial in achondroplasia.
-
The conference highlighted robust revenue growth, global expansion, and strong product uptake, especially for Skytrofa and Yorvipath. Strategic partnerships and pipeline innovation position the company for blockbuster status and potential cash flow break-even by year-end.
Fiscal Year 2024
-
Strong 2024 performance driven by Skytrofa and Yorvipath launches, with robust revenue growth, expanding market share, and a solid cash position. Yorvipath's U.S. launch shows high early demand, and further global expansion is underway. Continued pipeline progress and new collaborations support long-term growth.
-
Strong clinical and commercial progress was achieved across all rare endocrinology programs, with SkyTrofa and YorviPath showing robust growth and market positioning. Financially, revenue growth was offset by higher sales deductions, but guidance remains positive, supported by a major Novo Nordisk collaboration and a strong cash position.
-
The pivotal APPROACH trial showed TransCon CNP significantly increased annualized growth velocity and improved height Z-scores in children with achondroplasia, with a favorable safety profile and quality of life benefits. Regulatory submissions are planned for 2025, and all trial completers entered the open-label extension.
-
Yorvipath achieved strong US and EU launches with high retention, while Skytrofa volume doubled but Q2 revenue fell due to market access resets and true-ups. Full-year Skytrofa revenue is guided at €220–240M, with pivotal TransCon CNP data expected soon.
-
FDA approved Yorvipath as the first hormone replacement for adult hypoparathyroidism in the U.S., with a broad label and no REMS. Launch begins immediately, leveraging existing infrastructure, with robust efficacy and safety data supporting use.
-
Key pipeline products are advancing, with SKYTROFA surpassing 10,000 patients and YORVIPATH expanding across Europe. Regulatory milestones include an FDA PDUFA extension for TransCon PTH to August 2024, while pivotal data for TransCon CNP and oncology updates are expected by year-end.